跳至主要内容
临床试验/NCT00352261
NCT00352261已完成4 期

An Open-Label, 2-Way Crossover Study of Steady-State Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

AstraZeneca12 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2006年1月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
AstraZeneca
入组人数
80
试验地点
12
主要终点
Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients by evaluation of the percentage of time that intragastric pH is >4.0 over a 24 hr period steady state

研究概览

简要总结

The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Documented history (within 2 yrs of histologically proven BE;
  • Aged 18-70 (inclusive);
  • Willing and able to comply with all study procedures

排除标准

  • Signs of clinically significant GI bleeding within 3 days prior to randomization;
  • History of gastric or esophageal surgery;
  • Clinically significant illness within 2 weeks prior to first dose of study drug or during study

结局指标

主要结局

Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients by evaluation of the percentage of time that intragastric pH is >4.0 over a 24 hr period steady state

次要结局

  • Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg bid in controlling intragastric pH in BE patients by evaluation of the % of time intragastric pH is >4.0 over 24 hr period at steady state

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (12)

Loading locations...

相似试验